DEG Confirmed in Relife and Respifresh Cough Syrup in MP

Bhopal:  Madhya Pradesh food and drugs administration (MPFDA) Monday flagged two additional cough syrups, apart from the previously reported Coldrif, as “unsafe” after laboratory analysis revealed dangerously high levels of diethylene glycol (DEG) — a toxic chemical.

The syrups, manufactured under the brands Relife Batch No. LSL25160 and Respifresh TR Batch No. R01GL2523, contained DEG at concentrations of 0.6161% and 1.342% respectively, significantly above the safety threshold. Normally, any detectable level of DEG is considered hazardous for oral medications since it can cause acute poisoning, kidney failure, and death.

Former MPFDA commissioner Dinesh Kumar Maurya confirmed that the sale of the two contaminated cough syrups has been officially banned. Maurya was relieved of his duties later on Monday evening.

One of the manufacturers is based in Ahmedabad, while the other operates out of Rajkot. Legal proceedings have been initiated against both companies, and existing stocks of the syrups are being recalled for further testing.

These medications were among those administered to children affected in the Chhindwara incident involving Coldrif cough syrup. As part of the investigation into the cause and to uphold drug safety standards, authorities collected samples of 13 different medicines, including Coldrif. According to Maurya, three of these have now been identified as substandard.

According to state drug inspectors, both syrups also contained usual ingredients like ambroxol HCl, guaifenesin, terbutaline sulphate, and menthol, compounds commonly used to treat cough and cold symptoms. However, it is DEG contamination that makes the products extremely dangerous. Doctors warn that ingestion may lead to severe symptoms including abdominal pain, vomiting, kidney damage, and neurological issues.

Both products have now been classified as “non-standard quality,” prompting their immediate ban from pharmacies and hospital dispensaries.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states